Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 63Tumor-Agnostic 3Thoracic 2Other solid neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1NSCLC Harboring NRG1 Fusion 1Lymphoma, Follicular 1

Interventions

Carboplatin 191pembrolizumab 155Pemetrexed 134Cisplatin 117durvalumab 71Paclitaxel 71osimertinib 67Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 57Magnetic Resonance Spectroscopy 50Etoposide 46Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 20Platinum 20amivantamab 18Radiation 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
enzalutamide × Thoracic × 90 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡